<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020007</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067490</org_study_id>
    <secondary_id>NCI-00-C-0019</secondary_id>
    <nct_id>NCT00020007</nct_id>
    <nct_alias>NCT00001939</nct_alias>
  </id_info>
  <brief_title>Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery</brief_title>
  <official_title>A Phase I Study of Isolated Lung Perfusion With Paclitaxel and Moderate Hyperthermia in Patients With Unresectable Pulmonary Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Heating paclitaxel to several degrees above body temperature and&#xD;
      infusing it to the affected area around the tumor may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of paclitaxel given by&#xD;
      hyperthermic perfusion in treating patients with lung cancer or lung metastases that cannot&#xD;
      be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and phase II dose of paclitaxel administered via&#xD;
           hyperthermic retrograde isolated lung perfusion in patients with unresectable pulmonary&#xD;
           malignancies.&#xD;
&#xD;
        -  Determine the nature of the toxic effects of this regimen in this patient population.&#xD;
&#xD;
        -  Evaluate the pharmacokinetic profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine the relationship between pharmacodynamic parameters and toxic effects of this&#xD;
           regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of paclitaxel.&#xD;
&#xD;
      Patients undergo posterolateral thoracotomy or median sternotomy. Patients receive paclitaxel&#xD;
      over 90 minutes administered via hyperthermic retrograde isolated lung perfusion. The entire&#xD;
      surgery lasts approximately 4 hours.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of paclitaxel until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 1 and 2 months. Patients with responding disease continue to be&#xD;
      followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 31 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isolated perfusion</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hyperthermia treatment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed unresectable primary lung cancer or&#xD;
             pulmonary metastases that are unresectable on the basis of technical considerations or&#xD;
             are sufficiently numerous that recurrent, potentially inoperable disease is highly&#xD;
             probable&#xD;
&#xD;
               -  Bilateral metastases allowed&#xD;
&#xD;
               -  Unresectable bronchoalveolar carcinomas allowed&#xD;
&#xD;
               -  Previously treated primary lung cancer allowed&#xD;
&#xD;
          -  Disease outside confines of thorax allowed, provided bulk of disease in the chest is&#xD;
             clearly the greatest threat to survival and/or extrathoracic disease is controlled&#xD;
&#xD;
          -  No potentially treatable pulmonary metastases from lymphomas or germ cell tumors&#xD;
&#xD;
          -  No biopsy proven interstitial fibrosis, radiation induced pneumonitis, or evidence of&#xD;
             significant pulmonary hypertension by history, radiologic, echocardiographic, or&#xD;
             catheterization studies&#xD;
&#xD;
          -  No active intracranial or leptomeningeal metastases&#xD;
&#xD;
               -  Prior resection or radiotherapy for intracranial metastases allowed if the&#xD;
                  following criteria are met:&#xD;
&#xD;
                    -  No active disease on 2 MRIs done one month apart&#xD;
&#xD;
                    -  No requirement for anticonvulsant medications or steroids&#xD;
&#xD;
          -  Adequate pulmonary reserve to tolerate pneumonectomy:&#xD;
&#xD;
               -  Oxygen consumption greater than 50% predicted AND&#xD;
&#xD;
               -  FEV1 and DLCO greater than 80% predicted OR&#xD;
&#xD;
               -  FEV1 or DLCO less than 80% predicted allowed if postoperative FEV1 and DLCO is at&#xD;
                  least 40% predicted on the basis of split function V/Q scan&#xD;
&#xD;
          -  Prior radiotherapy to chest allowed provided 6 months have elapsed since completion of&#xD;
             treatment and no history of, nor current evidence of, interstitial lung disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 10 g/dL&#xD;
&#xD;
          -  WBC greater than 3,500/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  PT/PTT normal&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT less than 1.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.6 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Fixed defects on thallium scanning with ejection fraction greater than 40% allowed&#xD;
&#xD;
          -  Reversible or ischemic defects allowed only after cardiology clearance&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Resting oxygen saturation greater than 90%&#xD;
&#xD;
          -  pCO_2 less than 45 mmHg by arterial blood gas&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active infections&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  More than 30 days since prior biologic therapy for this malignancy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  More than 30 days since prior chemotherapy for this malignancy&#xD;
&#xD;
          -  Prior paclitaxel allowed&#xD;
&#xD;
          -  No prior bleomycin, nitrosoureas, or busulfan&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior thoracic surgery allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S. Schrump, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2006</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>limited stage small cell lung cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>lung metastases</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>pulmonary carcinoid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

